OmegaD LLC Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2016
NCT02980224
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

OmegaD LLC

Active Ingredients

Drugs in Phase 3 Trials (2)

icosapent ethyl (vascepa) (1 trial)

omega-3 fatty acids (Omacor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2